Clinical Trial Update: Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab plus ipilimumab in patients with hypermutated cancers detected in blood (NIMBLe) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Advanced Solid Tumors | Phase 2 | Status: TERMINATED | Results posted: 2024-02-22